Perspectives
Xeljanz® use for RA on the rise (but so is its discontinuation rate)
Nearly half of Xeljanz® users discontinue the costly RA drug after one year
February 9, 2017Prime research shows nearly half of Xeljanz® users discontinue the costly rheumatoid arthritis (RA) drug after one year
The FDA approved Tofacitinib (Xeljanz®) for people with RA who have an inadequate response to methotrexate. The study found that one in 10 members were potentially not following guidelines to use tofacitininb as second line therapy. Additionally, 44 percent of members discontinued the drug by one year. RA is a chronic condition that needs ongoing treatment; this study show there is opportunity for improvement. Plan sponsors should develop care and utilization management programs that encourage adherence and cost-effective treatment strategies.
Related news
Perspectives
August 15, 2022
September 2022 decisions expected from the FDA
At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to…
Perspectives
August 4, 2022
Specialty Pipeline Update: July 2022
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…
Perspectives
August 4, 2022
Traditional Drug Pipeline Update: July 2022
This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…